Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

toothbrush

- PMLiVE

Maximising impact in medical communications: where are we now and where are we heading?

By Ben Holtom

Engage Internal Teams Virtually – Engaging Your Advisors Creatively

Boost internal effectiveness! Learn a creative way to use virtual advisory boards to facilitate best practice-sharing with sales representatives and knowledge-sharing with MSLs. This is the key to aligning your...

Impetus Digital

- PMLiVE

The Mission to Humanize Healthcare

Medical and scientific innovation are in a fast lane closely pursued by digital advances but their dynamism can mute a vital element of progressive healthcare – patient integration.

Medscape Education

- PMLiVE

Roche’s Evrysdi tablets approved by MHRA to treat spinal muscular atrophy

It is hoped the new formulation will offer patients greater freedom and flexibility compared to the liquid version

- PMLiVE

Apogee Therapeutics’ atopic dermatitis candidate shows promise in phase 2 study

The inflammatory skin condition affects over 26 million people in the US

- PMLiVE

Empower or fall behind: why true patient engagement is pharma’s competitive edge

By Paul Allen

market access in Japan

Implementation of Cost-Effectiveness Analysis in Japan’s Health Technology Assessment Process

Japan’s evolving approach to market access includes a formal cost-effectiveness analysis (CEA) requirement for certain new medicines and medical devices. Introduced as part of a broader health technology assessment (HTA)...

Petauri Evidence

- PMLiVE

AstraZeneca’s Imfinzi/Imjudo regimen recommended by NICE to treat liver cancer

Approximately 6,600 people are diagnosed with liver cancer every year in the UK

- PMLiVE

Eli Lilly shares positive results for Jaypirca in head-to-head CLL/SLL study

Around 23,690 cases of chronic lymphocytic leukaemia are expected to be diagnosed in the US this year

- PMLiVE

Patient activation – not just a strategy but a necessity

By Becky Paul

- PMLiVE

BMS and Bain Capital launch new company to develop immunology therapies

The newly formed company has in-licensed five investigational immunology drugs from BMS

EU flag

CHMP recommends BeOne Medicines’ Tevimbra for new lung cancer indication

Non-small cell lung cancer accounts for up to 90% of all lung cancer cases

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links